 Two poster presentations showing AFM24 as a monotherapy and combination treatment will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, November 8-12, 2022. Results from the phase 2 registration REDIRECT study using AFM13 as a monotherapy for the treatment of patients with CD30-positive Peripheral T-cell lymphoma expected Q4 of 2022. 